Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.38 |
| ▸ | NT5E | P21589 | 6/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21765916 | 0.94 | ADORA3 (0.38) | P2RY1ADORA3ADORA1ADORA2ANT5E | |
| SCHEMBL21766033 | 0.91 | P2RY1 (0.40) | P2RY1ADORA3ADORA1ADORA2ANT5E | |
| SCHEMBL20180117 | 0.88 | ADORA3 (0.35) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL21766024 | 0.86 | ADORA1 (0.42) | P2RY1ADORA3ADORA1ADORA2ANT5E | |
| SCHEMBL20180115 | 0.80 | NT5E (0.59) | ADORA3ADORA1ADORA2ANT5EADORA2B | |
| SCHEMBL21766040 | 0.80 | ADORA1 (0.43) | P2RY1ADORA3ADORA1ADORA2ANT5E | |
| SCHEMBL21766008 | 0.78 | ADORA1 (0.41) | P2RY1ADORA3ADORA1ADORA2ANT5E | |
| SCHEMBL22215100 | 0.77 | P2RY1 (0.43) | P2RY1ADORA3ADORA1ADORA2ANT5E | |
| SCHEMBL21766026 | 0.76 | ADORA3 (0.42) | P2RY1ADORA3ADORA1ADORA2ANT5E | |
| SCHEMBL20180326 | 0.74 | ADORA3 (0.58) | ADORA3ADORA1ADORA2ANT5EADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11267845-B2 | Inhibitors of CD73-mediated immunosuppression | ARCUS BIOSCIENCES, INC. (US) | 2022-03-08 | — | — | US | disclosed |
| US-20200062797-A1 | INHIBITORS OF CD73-MEDIATED IMMUNOSUPPRESSION | ARCUS BIOSCIENCES, INC. | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062797-A1 | INHIBITORS OF CD73-MEDIATED IMMUNOSUPPRESSION | ENTPD5, NT5E, ENTPD1 | P2RY1 58/4885ADORA3 28/4885ADORA1 29/4885 |
| US-11267845-B2 | Inhibitors of CD73-mediated immunosuppression | ENTPD5, NT5E, ENTPD1 | P2RY1 58/4885ADORA3 28/4885ADORA1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.